ASCL2 and prostate carcinoma: Recently, multiple single-cell analyses have identified a subpopulation of NEPC cells with high expression of POU2F3 and its downstream target ASCL2 in both prostate cancer patients and genetically engineered mouse models (GEMMs)40–43.